Tradestie Institutional Equity Comparison Engine

OBIO vs VIVS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OBIO Overall Edge

OBIO Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, OBIO sits in BREAKOUT (21st %ile IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
OBIO N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner OBIO
Op Margin -195.4% vs -10117.0% ยท YoY -89.4% vs -51.4%
Momentum & Technical Winner OBIO
1Y +65.5% vs -87.0% ยท 52W Pos 81% vs 5%
Options & Structure Winner OBIO
BREAKOUT (21st %ile IV) vs BREAKDOWN (N/A IV)
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.00
-6.17% 1D
Market Cap $587.1M
1M Return +20.59%
1Y Return +65.48%
Forward P/E N/M
Unified AI Score
37.8 / 100 SELL
Tech 50.0 Fund 36.0 Flow 68.0 Mom 50.0
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OBIO +65.48% VIVS -86.99% Spread: +152.47 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OBIO Revenue VIVS Revenue OBIO Op. Margin VIVS Op. Margin Margin Edge
FY2018 N/A $0M N/A -766.3% VIVS
FY2019 N/A $0M N/A -882.4% VIVS
FY2020 N/A $0M N/A -977.9% VIVS
FY2022 $0M $0M -924.3% -765.3% VIVS
FY2023 $0M $0M -1866.2% -4792.2% OBIO
FY2024 $0M $0M -2437.5% -13840.4% OBIO
FY2025 $30M $0M -154.7% -8761.1% OBIO
FY2026 N/A $0M N/A -8768.7% VIVS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OBIO (6) vs VIVS (2)
Institutional Metric OBIO VIVS Criterion Row Winner
Market Capitalization Scale $587.1M $2.4M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -89.4% -51.4% Higher Growth VIVS
Operating Margin (TTM) Profitability -195.4% -10117.0% Higher Margin OBIO
Net Profit Margin Profitability -182.5% 0.0% Higher Margin VIVS
Return on Equity (ROE) Capital Efficiency -182.3% -343.1% Higher ROE OBIO
52-Week Range Position Momentum 81% ($3โ€“$8) 5% ($0โ€“$3) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.14ฮฒ ยท 86% Vol 0.83ฮฒ ยท 480% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 37.8 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite OBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OBIO vs VIVS Buy Guide
OBIO BREAKOUT
35d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OBIO nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.